<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657085</url>
  </required_header>
  <id_info>
    <org_study_id>LUM-ABU-HSET-0607-02</org_study_id>
    <nct_id>NCT00657085</nct_id>
  </id_info>
  <brief_title>Evaluation of the LightSheer HS Hand Piece as Compared to the LightSheer ET Hand Piece for the Intended Use of Hair Removal and Permanent Hair Reduction</brief_title>
  <official_title>Evaluation of the LightSheer HS Hand Piece as Compared to the LightSheer ET Hand Piece for the Intended Use of Hair Removal and Permanent Hair Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumenis Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumenis Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the qualitative comparison of follicular damage between treatment with the&#xD;
      LightSheer Duet hand pieces (ET and HS) as assessed by horizontal biopsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Follicular damage assessed by histology</measure>
    <time_frame>first visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of permanent hair reduction between ET and HS handpieces</measure>
    <time_frame>2 month follow up visit</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Laser Hair Removal</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsied hair follicles retained and analzed through horizontal sectioning and viability&#xD;
      staining&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        5 Adult male subjects that have sought laser back hair removal&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male adult, 18 years of age or older with skin type I-V;&#xD;
&#xD;
          2. Having a suitable treatment area for hair removal with brown or black hair (no gray);&#xD;
&#xD;
          3. Able and willing to comply with the treatment/follow-up schedule and requirements;&#xD;
&#xD;
          4. Able to read, understand and provide written Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Showing symptoms of hormonal disorders, as per the Investigator's discretion;&#xD;
&#xD;
          2. Use of oral isotretinoin (AccutaneÂ®) within 6 months, or off label use of topical&#xD;
             isotretinoin in immediate treated area or in its proximity within 3 months, of study&#xD;
             enrollment or during the course of the study;&#xD;
&#xD;
          3. Prior skin treatment with laser or other devices on the same treated areas prior to&#xD;
             study enrollment or during the course of the study;&#xD;
&#xD;
          4. Adverse reaction to the treatment gel to be used in the evaluation;&#xD;
&#xD;
          5. History of keloid formation or poor wound healing in a previously injured skin area;&#xD;
&#xD;
          6. Significant skin conditions affecting treated area or inflammatory skin conditions;&#xD;
&#xD;
          7. Open laceration, abrasion, active cold sores or herpes sores on area to be treated;&#xD;
&#xD;
          8. History of immunosuppression/immune deficiency disorders (including HIV infection or&#xD;
             AIDS) or use of immunosuppressive medications;&#xD;
&#xD;
          9. Having a bleeding disorder or taking anticoagulation medications within the preceding&#xD;
             6 months;&#xD;
&#xD;
         10. Having or undergoing any form of treatment for active cancer, or having a history of&#xD;
             skin cancer or any other cancer in the area to be treated;&#xD;
&#xD;
         11. Significant concurrent illness, such as diabetes, lupus, epilepsy or cardiac&#xD;
             disorders, which might be aggravated as a result of treatment;&#xD;
&#xD;
         12. Unable or unlikely to refrain from tanning, including the use of tanning booths,&#xD;
             tanning spray or cream, during the course of the evaluation;&#xD;
&#xD;
         13. Photosensitivity disorder that can be exacerbated by infrared light;&#xD;
&#xD;
         14. Tattoos in the treatment areas;&#xD;
&#xD;
         15. Dysplastic nevi in the treatment areas;&#xD;
&#xD;
         16. Allergy or history of an allergy to the topical anesthetic used.&#xD;
&#xD;
         17. Participation in a study of another device or drug within 3 months prior to study&#xD;
             enrollment or during this study, and as per the Investigator's careful discretion, as&#xD;
             long as not contradictory to any of the above criteria;&#xD;
&#xD;
         18. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;&#xD;
&#xD;
         19. Any condition which, in the Investigator's opinion, would make it unsafe (for the&#xD;
             subject or for the study personnel) to treat the subject as part of this research&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seaver Soon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seaver Soon</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>December 10, 2008</last_update_submitted>
  <last_update_submitted_qc>December 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Chris Clark</name_title>
    <organization>Lumenis</organization>
  </responsible_party>
  <keyword>Laser hair removal</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

